UPDATE: Roth Capital Downgrades JinkoSolar Holding Co., Ltd. (JKS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Increasing unusual put option volume: RSX TBT PHM JKS ASO CYBR RSP MGA
April 9, 2021 10:57 AM EDTIncreasing unusual put option volume: RSX TBT PHM JKS ASO CYBR RSP MGA
... MorePre-Open Stock Movers 04/09: (CELC) (AFMD) (GLSI) Higher; (PRVB) (ITRM) (JKS) Lower (more...)
April 9, 2021 9:31 AM EDTToday's Pre-Open Stock Movers
Celcuity Inc. (Nasdaq: CELC) 63% HIGHER; reported preliminary data for the 103 patients enrolled in the expansion portion of an ongoing Phase 1b clinical trial evaluating gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus Ibrance and endocrine therapy, in ER+/HER2- advanced or metastatic breast cancer patients. As of the January 11, 2021 data cut-off date, 53 of the 88 evaluable patients (60%) had an objective response. Gedatolisib was also generally well tolerated, with the majority of treatment-related adverse events (TRAE) being Grade 1 or 2. The most common Grade 3 or 4... More
JinkoSolar (JKS) Misses Q4 EPS by 25c, Revenue Beats, Offers Guidance
April 9, 2021 7:27 AM EDTJinkoSolar (NYSE: JKS) reported Q4 EPS of $0.11, $0.25 worse than the analyst estimate of $0.36. Revenue for the quarter came in at $1.44 billion versus the consensus estimate of $1.38 billion.
GUIDANCE:
JinkoSolar sees Q1 2021 revenue of $1.18-1.3 billion, versus the... More
